READ / RESEARCH · ELECTRICAL VESTIBULAR NERVE STIMULATION

This paper tests a portable headset that sends a small electrical current through pads behind the ears, aiming to stimulate the vestibular system involved in balance. Participants used it at home for 30 minutes daily over four weeks. The active device did not clearly outperform the sham device across the full analysed group. A benefit appeared in the subgroup with moderate-to-severe anxiety.

Why I looked at this

My sticky notes identify two useful starting points: electrical vestibular nerve stimulation (VeNS) delivers a small current through the skin, and the Modius MA1500 is a portable, battery-operated device.

This interests me as another example of a wearable intended to influence bodily processes without requiring the person to follow a breathing rhythm. For my project, I need to understand both the technology and whether the evidence relates to support during an airport journey.

How the technology works

The headset uses electrode pads placed over the mastoid processes: the bony areas behind the ears. It applies electrical stimulation intended to influence the vestibular system, which helps with balance and spatial orientation.

This is different from the ultrasound paper. The technologies use different forms of stimulation and target different nerve pathways. A similar position around the head does not make their mechanisms or evidence interchangeable.

In this trial, participants adjusted the stimulation until they felt a gentle swaying sensation. They were instructed to use it while seated and before sleeping. The study therefore describes a structured treatment session, rather than a device tested while walking around or navigating a busy environment.

The authors discuss possible connections between vestibular stimulation and emotional regulation, but they did not directly test the neural mechanism. I should describe the mechanism as proposed rather than proven by these results.

What the researchers tested

The study used a randomised, double-blind, sham-controlled design. Participants received either an active headset or a similar-looking comparison device that delivered brief stimulation before tapering off. This provides a stronger comparison than simply measuring people before and after treatment.

The trial randomised 87 participants; the reported intention-to-treat analysis included 80, with 71 completing the intervention. Although recruitment targeted moderate-to-severe anxiety, some participants’ scores fell between screening and baseline. Those with at least mild symptoms at baseline could continue.

Anxiety was assessed using the GAD-7 questionnaire before and after 28 days. Insomnia and quality of life were also assessed.

What the results actually show

Across all 80 analysed participants, anxiety scores improved in both groups. The average reduction was 4.95 points with the active device and 3.90 with sham stimulation. The difference between groups was not statistically significant (p = 0.269).

Within the 53-person subgroup with moderate-to-severe anxiety at baseline, the active group improved more in the reported model accounting for usage (p = 0.045). However, the proportion achieving a clinically meaningful reduction of at least four points did not differ significantly between groups.

There were also no significant between-group benefits for insomnia or the measured quality-of-life components. The paper’s positive title therefore needs to be read alongside these narrower findings.

The encouraging finding concerns a subgroup after four weeks. It does not demonstrate immediate calming, or a clear benefit across everyone studied.

Comfort and practical limitations

No serious adverse events were reported, but some participants stopped treatment because of symptoms. Reported reasons included headaches, tiredness, disrupted sleep and brain fog; one participant withdrew after reporting migraine and increased anxiety with mood swings.

This matters for my project because the sensory experience is part of the intervention. A swaying sensation, skin contact or tingling might be acceptable to one person and unwelcome to another. Portability alone does not establish suitability for use during travel.

Participants could operate the device after a video training session, which is a useful example of supporting use at home. However, the trial did not establish suitability for autistic adults, sensory overload or airport conditions. It also excluded people with several health conditions, including vestibular disorders.

How I am judging the evidence

The sham comparison is a strength, but the study relied on self-reported outcomes and there may have been some unblinding. It also did not establish how long benefits lasted beyond the four-week intervention.

Neurovalens funded the study and was involved in its concept, design, device provision and decision to submit the paper. The authors reported no conflicts of interest. I would retain that funding context when assessing the findings.

The device recorded usage, but this was not a biosensing-controlled system. There was no demonstrated process in which changing physiological signals triggered or adapted stimulation.

What I am taking forward

I am keeping VeNS as a research reference for wearable neuromodulation, with a cautious view of its relevance to my project. The paper helps distinguish a portable treatment device from a response that can usefully support someone during a particular stressful moment.

Before considering this direction further, I would need evidence about my intended audience, the acceptability of the sensations and whether the timing suits travel. The current study does not justify assuming that adding live biosensing would make it an effective airport intervention.

The key design question is not only whether a device can be worn. It is whether its sensations, timing and demands fit the person and the situation.

Source

Curry, G., Zhang, S.-D., McAnena, L., Price, R. K. and Sittlington, J. J. (2026). ‘Repeated Electrical Vestibular Nerve Stimulation Reduces Anxiety in People With Moderate-to-Severe Anxiety: A Randomized, Sham-Controlled Trial: The Modius Anxiety Study’. Neuromodulation, 29(4), pp. 626–636.

Key reading: device and study design, p. 627; adverse events and main results, pp. 630–632; strengths and limitations, p. 633; further research and funding involvement, p. 634. Page references use the article’s printed numbering.